The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | MDS in younger patients: the importance of curative approaches & optimizing timing of alloSCT
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the optimal treatment strategy for younger patients with myelodysplastic syndromes (MDS), highlighting the need for curative approaches and the importance of optimizing timing for allogeneic stem cell transplantation (alloSCT). He emphasizes the potential of new technologies, including artificial intelligence, to make informed decisions for individual patients. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
With respect to MDS, we know that the median age of diagnosis is around 60 to 70 years. So this means that this pathology is rare in younger patients. But for sure, a young patient with MDS is associated with a strong clinical need. In general terms, the optimal treatment strategy for this rare population of young patients with MDS is to try to cure the disease. The only available treatment with a potential curative effect is allogeneic stem cell transplantation...
With respect to MDS, we know that the median age of diagnosis is around 60 to 70 years. So this means that this pathology is rare in younger patients. But for sure, a young patient with MDS is associated with a strong clinical need. In general terms, the optimal treatment strategy for this rare population of young patients with MDS is to try to cure the disease. The only available treatment with a potential curative effect is allogeneic stem cell transplantation. The most relevant need is to optimize the timing of the procedure at an individual patient level. And again, I think that new technologies, including artificial intelligence, can help us make the right decision for each individual patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
